• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
IMU
Click for more information
4.26% 4.5¢

IMUGENE LIMITED - Announcements

Market Cap $386.7M  ! watchlist Created with Sketch. Add to my watchlist

Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing... Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness and promote the body’s immune system against cancerous tumors. Its product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug Azer-Cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia (pox) virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Its Chimeric antigen receptor (CAR)-engineered T cells (CAR T) are T cells redirected against tumors through engineered expression of CARs. More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
IMUIMU Commences FDA IND Process for Gastric Cancer vaccinePRICE SENSITIVE17/03/14
IMUHalf Yearly Report and AccountsPRICE SENSITIVE27/02/14
IMUImugene Investor Update25/02/14
IMUAppendix 4C - quarterlyPRICE SENSITIVE29/01/14
IMUScientific Advisory Board Appointments20/01/14
IMUChange of Director's Interest Notice24/12/13
IMUBecoming a substantial holder24/12/13
IMUInitial Director's Interest Notice24/12/13
IMUBecoming a substantial holder23/12/13
IMUChange of Director's Interest Notice23/12/13
IMUFinal Director's Interest Notice23/12/13
IMUBecoming a substantial holder23/12/13
IMUBecoming a substantial holder23/12/13
IMUBecoming a substantial holder20/12/13
IMUSettlement of Biolife Science Qld Ltd Acquisition20/12/13
IMUAppendix 3B and Section 708A Notice20/12/13
IMUResults of Meeting20/12/13
IMUImugene Secures Important Intellectual PropertyPRICE SENSITIVE19/12/13
IMUInvestor Presentation10/12/13
IMUAppendix 3B and Section 708A Notice09/12/13
IMUResults of Meeting20/11/13
IMUAGM Presentation20/11/13
IMUNotice of General Meeting/Proxy Form18/11/13
IMUAppointment of Dr Axel Hoos as a Non-Executive Director06/11/13
IMUPrivate Placement04/11/13
IMUAppendix 3B & Section 708A Notice31/10/13
IMUAppendix 4C - quarterlyPRICE SENSITIVE24/10/13
IMUCapital Raising CompletePRICE SENSITIVE23/10/13
IMUPresentation and Q&A - Acquisition of Biolife Science Qld23/10/13
IMUImugene to acquire Biolife Science Qld LimitedPRICE SENSITIVE23/10/13
IMUTrading HaltPRICE SENSITIVE21/10/13
IMUNotice of Annual General Meeting/Proxy Form21/10/13
IMUCeasing to be a substantial holder - JP16/10/13
IMUAnnual Report to shareholders27/09/13
IMUEuropean patent for novel drug delivery technologyPRICE SENSITIVE27/09/13
IMUUpdated Securities Trading Policy25/09/13
CGP +Change in substantial holding from CGP20/09/13
IMUBecoming a substantial holder20/09/13
CGP +Shareholder UpdatePRICE SENSITIVE19/09/13
IMUImugene discontinues ibuprofen developmentPRICE SENSITIVE18/09/13
IMUAppendix 3B and Section 708A Notice04/09/13
IMUPreliminary Final ReportPRICE SENSITIVE29/08/13
IMUCeasing to be a substantial holder14/08/13
IMUVitamin D development program at commercialisation stagePRICE SENSITIVE08/08/13
IMUJapanese patent for novel drug delivery technologyPRICE SENSITIVE07/08/13
IMUAppendix 3B - Release of shares from escrow01/08/13
IMUAppendix 4C - quarterlyPRICE SENSITIVE29/07/13
IMURelease of Shares from Escrow11/07/13
IDT +Progress on Linguet Ibuprofen formulationPRICE SENSITIVE02/07/13
IMUChange of Director's Interest Notice07/06/13
IMUAppendix 3B - Share Purchase Plan04/06/13
IMUShare Purchase Plan Results & $181K R&D RefundPRICE SENSITIVE04/06/13
IMUImugene progresses Vitamin D development programPRICE SENSITIVE23/05/13
IMUResearch Report on Imugene Drug Delivery Technology08/05/13
IMUShareholder Newsletter02/05/13
IMUInvestor Presentation01/05/13
IMUShare Purchase Plan - Offer DocumentPRICE SENSITIVE30/04/13
IMUShare Purchase PlanPRICE SENSITIVE30/04/13
IMUShare Purchase Plan - Cleansing Notice30/04/13
IMUImugene granted Chinese patentPRICE SENSITIVE30/04/13
IMUAppendix 4C - quarterlyPRICE SENSITIVE29/04/13
IMUImugene to be awarded Japanese patentPRICE SENSITIVE05/03/13
IMUHalf Year Financial ResultsPRICE SENSITIVE28/02/13
IMUHalf Yearly Report and AccountsPRICE SENSITIVE28/02/13
IMUAppendix 3B & 708A Notice13/02/13
IMUAppendix 3Z - Final Director's Interest Notice (FP)13/02/13
IMUAppendix 3X - Initial Director's Interest Notice (NE)13/02/13
IMUReply to Query - Appendix 4CPRICE SENSITIVE11/02/13
IMUImugene Announces Board and Management Changes11/02/13
IMUAppendix 4C - quarterlyPRICE SENSITIVE31/01/13
IMUAppointment of joint Company Secretary20/12/12
IMUResults of Meeting30/11/12
IMUChairman's Address & CTO Presentation30/11/12
IMUInvestor Presentation20/11/12
IMUInitial Director's Interest Notice06/11/12
CGP +Consegna Elects to return Aspen MedisysPRICE SENSITIVE01/11/12
IMUFinal Director's Interest Notice31/10/12
IMUAppendix 4C - quarterlyPRICE SENSITIVE31/10/12
IMUChanges to the Board of DirectorsPRICE SENSITIVE31/10/12
IMUNotice of Annual General Meeting/Proxy Form29/10/12
IMUAnnual Report to shareholders29/10/12
IMUFinal Director's Interest Notice03/10/12
IMUResignation of Director02/10/12
CGP +Imugene announces details of drug delivery program20/09/12
IMUImugene announces details of drug delivery programPRICE SENSITIVE20/09/12
IMUResponse to ASX QueryPRICE SENSITIVE12/09/12
IMUAppendix 4E and Financial ReportPRICE SENSITIVE31/08/12
IMUNotice under section 708A of the Corporations Act13/08/12
IMUBecoming a substantial holder13/08/12
IMUAppendix 3B09/08/12
IMUDetails of Company Address03/08/12
IMUAppendix 3X - Steve Harris Initial Directors Notice01/08/12
IMUBoard Appointment & New DirectionPRICE SENSITIVE01/08/12
CGP +Becoming a substantial holder from CGP31/07/12
IMUAppendix 3X - Fabio Pannuti Initial Interest Notice31/07/12
IMUAppendix 3Z - Graham Dowland Final Interest Notice31/07/12
IMUAppendix 3B31/07/12
IMUAcquisition Completed, Board Changes & Share PlacementPRICE SENSITIVE31/07/12
IMUQuarterly Shareholder Update & Appendix 4CPRICE SENSITIVE31/07/12
CGP +Imugene Limited shareholders approve Linguet acquisition17/07/12
IMUIMU Commences FDA IND Process for Gastric Cancer vaccine
17/03/14PRICE SENSITIVE
IMUHalf Yearly Report and Accounts
27/02/14PRICE SENSITIVE
IMUImugene Investor Update
25/02/14
IMUAppendix 4C - quarterly
29/01/14PRICE SENSITIVE
IMUScientific Advisory Board Appointments
20/01/14
IMUChange of Director's Interest Notice
24/12/13
IMUBecoming a substantial holder
24/12/13
IMUInitial Director's Interest Notice
24/12/13
IMUBecoming a substantial holder
23/12/13
IMUChange of Director's Interest Notice
23/12/13
IMUFinal Director's Interest Notice
23/12/13
IMUBecoming a substantial holder
23/12/13
IMUBecoming a substantial holder
23/12/13
IMUBecoming a substantial holder
20/12/13
IMUSettlement of Biolife Science Qld Ltd Acquisition
20/12/13
IMUAppendix 3B and Section 708A Notice
20/12/13
IMUResults of Meeting
20/12/13
IMUImugene Secures Important Intellectual Property
19/12/13PRICE SENSITIVE
IMUInvestor Presentation
10/12/13
IMUAppendix 3B and Section 708A Notice
09/12/13
IMUResults of Meeting
20/11/13
IMUAGM Presentation
20/11/13
IMUNotice of General Meeting/Proxy Form
18/11/13
IMUAppointment of Dr Axel Hoos as a Non-Executive Director
06/11/13
IMUPrivate Placement
04/11/13
IMUAppendix 3B & Section 708A Notice
31/10/13
IMUAppendix 4C - quarterly
24/10/13PRICE SENSITIVE
IMUCapital Raising Complete
23/10/13PRICE SENSITIVE
IMUPresentation and Q&A - Acquisition of Biolife Science Qld
23/10/13
IMUImugene to acquire Biolife Science Qld Limited
23/10/13PRICE SENSITIVE
IMUTrading Halt
21/10/13PRICE SENSITIVE
IMUNotice of Annual General Meeting/Proxy Form
21/10/13
IMUCeasing to be a substantial holder - JP
16/10/13
IMUAnnual Report to shareholders
27/09/13
IMUEuropean patent for novel drug delivery technology
27/09/13PRICE SENSITIVE
IMUUpdated Securities Trading Policy
25/09/13
CGP +Change in substantial holding from CGP
20/09/13
IMUBecoming a substantial holder
20/09/13
CGP +Shareholder Update
19/09/13PRICE SENSITIVE
IMUImugene discontinues ibuprofen development
18/09/13PRICE SENSITIVE
IMUAppendix 3B and Section 708A Notice
04/09/13
IMUPreliminary Final Report
29/08/13PRICE SENSITIVE
IMUCeasing to be a substantial holder
14/08/13
IMUVitamin D development program at commercialisation stage
08/08/13PRICE SENSITIVE
IMUJapanese patent for novel drug delivery technology
07/08/13PRICE SENSITIVE
IMUAppendix 3B - Release of shares from escrow
01/08/13
IMUAppendix 4C - quarterly
29/07/13PRICE SENSITIVE
IMURelease of Shares from Escrow
11/07/13
IDT +Progress on Linguet Ibuprofen formulation
02/07/13PRICE SENSITIVE
IMUChange of Director's Interest Notice
07/06/13
IMUAppendix 3B - Share Purchase Plan
04/06/13
IMUShare Purchase Plan Results & $181K R&D Refund
04/06/13PRICE SENSITIVE
IMUImugene progresses Vitamin D development program
23/05/13PRICE SENSITIVE
IMUResearch Report on Imugene Drug Delivery Technology
08/05/13
IMUShareholder Newsletter
02/05/13
IMUInvestor Presentation
01/05/13
IMUShare Purchase Plan - Offer Document
30/04/13PRICE SENSITIVE
IMUShare Purchase Plan
30/04/13PRICE SENSITIVE
IMUShare Purchase Plan - Cleansing Notice
30/04/13
IMUImugene granted Chinese patent
30/04/13PRICE SENSITIVE
IMUAppendix 4C - quarterly
29/04/13PRICE SENSITIVE
IMUImugene to be awarded Japanese patent
05/03/13PRICE SENSITIVE
IMUHalf Year Financial Results
28/02/13PRICE SENSITIVE
IMUHalf Yearly Report and Accounts
28/02/13PRICE SENSITIVE
IMUAppendix 3B & 708A Notice
13/02/13
IMUAppendix 3Z - Final Director's Interest Notice (FP)
13/02/13
IMUAppendix 3X - Initial Director's Interest Notice (NE)
13/02/13
IMUReply to Query - Appendix 4C
11/02/13PRICE SENSITIVE
IMUImugene Announces Board and Management Changes
11/02/13
IMUAppendix 4C - quarterly
31/01/13PRICE SENSITIVE
IMUAppointment of joint Company Secretary
20/12/12
IMUResults of Meeting
30/11/12
IMUChairman's Address & CTO Presentation
30/11/12
IMUInvestor Presentation
20/11/12
IMUInitial Director's Interest Notice
06/11/12
CGP +Consegna Elects to return Aspen Medisys
01/11/12PRICE SENSITIVE
IMUFinal Director's Interest Notice
31/10/12
IMUAppendix 4C - quarterly
31/10/12PRICE SENSITIVE
IMUChanges to the Board of Directors
31/10/12PRICE SENSITIVE
IMUNotice of Annual General Meeting/Proxy Form
29/10/12
IMUAnnual Report to shareholders
29/10/12
IMUFinal Director's Interest Notice
03/10/12
IMUResignation of Director
02/10/12
CGP +Imugene announces details of drug delivery program
20/09/12
IMUImugene announces details of drug delivery program
20/09/12PRICE SENSITIVE
IMUResponse to ASX Query
12/09/12PRICE SENSITIVE
IMUAppendix 4E and Financial Report
31/08/12PRICE SENSITIVE
IMUNotice under section 708A of the Corporations Act
13/08/12
IMUBecoming a substantial holder
13/08/12
IMUAppendix 3B
09/08/12
IMUDetails of Company Address
03/08/12
IMUAppendix 3X - Steve Harris Initial Directors Notice
01/08/12
IMUBoard Appointment & New Direction
01/08/12PRICE SENSITIVE
CGP +Becoming a substantial holder from CGP
31/07/12
IMUAppendix 3X - Fabio Pannuti Initial Interest Notice
31/07/12
IMUAppendix 3Z - Graham Dowland Final Interest Notice
31/07/12
IMUAppendix 3B
31/07/12
IMUAcquisition Completed, Board Changes & Share Placement
31/07/12PRICE SENSITIVE
IMUQuarterly Shareholder Update & Appendix 4C
31/07/12PRICE SENSITIVE
CGP +Imugene Limited shareholders approve Linguet acquisition
17/07/12
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
4.5¢ 		Change
-0.002(4.26%) 		Mkt cap ! $386.7M
Open High Low Value Volume
4.7¢ 4.8¢ 4.4¢ $890.8K 19.42M

Buyers (Bids)

No. Vol. Price($)
2 176601 4.5¢
 

Sellers (Offers)

Price($) Vol. No.
4.6¢ 969572 8
View Market Depth
Last trade - 16.10pm 06/11/2024 (20 minute delay) ?
Last
4.5¢ 		  Change
-0.002 ( 2.81 %)
Open High Low Volume
4.8¢ 4.8¢ 4.5¢ 9435451
Last updated 15.59pm 06/11/2024 ?
IMU (ASX) Chart

Top Stories

Bitcoin jumps 8% to beat record on Trump vote optimism

Bitcoin has been a big winner on financial markets today, tracking Donald Trump's election highs with an 8% rise and beating a previous record
Nanocap Si6 Metals to kick off drilling at Monument gold project WA, chasing past hits Nanocap Si6 Metals (ASX:SI6) is on the cusp of kicking off drilling at its Monument project in WA, sniffing after historical gold hit targets.
The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint Let’s get straight to the point: of all the smallcaps in the Telecommunications index, The Market Ltd could be one of the most overlooked.
Lord picks up high-grade copper play in Western Australia, with past intercepts of up to 6.62% Lor Resources Ltd has entered into a binding earn-in agreement with Blackrock Resources Pty Ltd to take on up to 80% of the Ilgarari project
Palladium's the newest geopolitical hot commodity. But ASX exposure is limited On October 24, the USA reportedly approached its G7 counterparts and proposed a ban on Russian titanium, and, palladium.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.